Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 6/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322832 | 1.00 | ADRB2 (0.54) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6322846 | 0.90 | ADRB2 (0.63) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6322852 | 0.90 | ADRB2 (0.63) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6323862 | 0.87 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6323866 | 0.87 | ADRB2 (0.58) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6319499 | 0.86 | KMT2A (0.63) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6319503 | 0.86 | KMT2A (0.63) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6320439 | 0.83 | ADRB1 (0.52) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6320443 | 0.83 | ADRB1 (0.52) | ADRB2ADRB1ADRB3CYP2D6KMT2A | |
| SCHEMBL6322699 | 0.82 | MAPT (0.62) | ADRB2ADRB1ADRB3CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820957-B2 | Low molecular weight amide/ester containing quaternary ammonium salts | THE LUBRIZOL CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-20210214639-A1 | LOW MOLECULAR WEIGHT AMIDE/ESTER CONTAINING QUATERNARY AMMONIUM SALTS | THE LUBRIZOL CORPORATION | 2021-07-15 | — | — | US | disclosed |
| US-6870005-B1 | Olefin-based thermoplastic alloy, process for making the same and molded parts containing the same | ACI TECHNOLOGIES, LLC (US) | 2005-03-22 | — | — | US | disclosed |
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-6670421-B1 | Olefin-polyamide thermoplastic alloy and process for making the same | ACI TECHNOLOGIES, LLC | 2003-12-30 | — | — | US | disclosed |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-0137518-B1 | BLENDS OF POLYOLEFIN GRAFT POLYMERS AND ASA POLYMERS, SMA POLYMERS AND CONDENSATION POLYMERS | OCCIDENTAL CHEMICAL CORPORATION (US) | 1987-10-21 | — | — | EP | disclosed |
| US-4562229-A | OMPROVED MOLAR MISCIBILITY | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-12-31 | — | — | US | disclosed |
| EP-0137518-A2 | Blends of polyolefin graft polymers and ASA polymers, SMA polymers and condensation polymers | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4454300-A | Blends of vinyl halide-polyolefin graft polymers and SMA polymers | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB2 3/4885ADRB1 1/4885ADRB3 2/4885 |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB2 3/4885ADRB1 1/4885ADRB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.